Poster
A 29-day two-dose and 3-day one-dose research and development study of intrathecal injection or epidural infusion in rats
November 17, 2024
ACT 2024 -- Treatment for neurological disorders is widely an unmet need. According to Feigin et al., 15 neurological disorders were identified to be the underlying cause in approximately 9 million global deaths in 2016. Administration directly into the intrathecal (IT) or epidural spaces bypasses the blood-brain barrier to enhance CNS drug distribution and efficacy while reducing systemic drug exposure and side effects. The purpose of this study was to evaluate the tolerability and feasibility of IT injection of Omnipaque 300 and/or artificial cerebral spinal fluid (aCSF) or epidural infusion of Omnipaque 300 and sterile saline in rats.